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Clinical PerspectiveWhat Is New?In this statewide study of all admissions for heart failure (HF) over a 7‐year period, adults with congenital heart disease (CHD)---who are otherwise younger and have fewer comorbidities than non‐CHD patients---nonetheless had significantly higher adjusted risks of adverse clinical outcomes.Adults with CHD had a 3.5% incidence of new arrhythmias during their admission for HF, representing nearly 3‐fold higher adjusted odds than non‐CHD patients.Adults admitted for HF with CHD had ≈2‐fold higher adjusted odds of longer length of stay and in‐hospital mortality than those without CHD.What Are the Clinical Implications?These data on adverse clinical outcomes for adults with CHD who are admitted for HF highlight the challenges faced by CHD and HF specialists.Higher odds of incident arrhythmias and mortality during HF hospitalization among CHD patients suggests a need to develop risk prediction tools; these tools might guide clinicians caring for these patients to make appropriate management decisions.Targeted CHD‐specific prevention and treatment protocols for HF need to be developed to reduce the high burden of adverse clinical outcomes during HF admissions.

Introduction {#jah34352-sec-0008}
============

Congenital heart disease (CHD) is the most common type of birth defect.[1](#jah34352-bib-0001){ref-type="ref"} Improved surgical and pediatric CHD care has increased the number of patients surviving to adulthood, including those with complex CHD.[2](#jah34352-bib-0002){ref-type="ref"}, [3](#jah34352-bib-0003){ref-type="ref"} It is estimated that there are \>1.5 million CHD adults currently in the United States.[4](#jah34352-bib-0004){ref-type="ref"}, [5](#jah34352-bib-0005){ref-type="ref"} Initial surgeries or interventions for CHD often are not curative, and patients frequently develop cardiac complications, including heart failure (HF).[6](#jah34352-bib-0006){ref-type="ref"} HF management in the setting of CHD is challenging because of the heterogeneity of the underlying anatomy and surgical repairs, and the paucity of evidence‐based management protocols.[6](#jah34352-bib-0006){ref-type="ref"}, [7](#jah34352-bib-0007){ref-type="ref"}

Prior studies have shown that there has been an increasing burden of inpatient hospitalizations, associated costs, and mortality from HF among adult CHD patients.[8](#jah34352-bib-0008){ref-type="ref"}, [9](#jah34352-bib-0009){ref-type="ref"}, [10](#jah34352-bib-0010){ref-type="ref"}, [11](#jah34352-bib-0011){ref-type="ref"} However, studies of in‐hospital clinical outcomes for adults with CHD during a HF hospitalization are lacking. Additionally, it has been shown that, after an index HF admission, 25% of patients get readmitted within 30 days for any cause; 35% get readmitted again for HF.[12](#jah34352-bib-0012){ref-type="ref"} But this study did not report readmission rates in CHD patients specifically. Information about clinical outcomes during HF admission and the rate of readmission within 30 days for CHD patients might help physicians treating CHD to develop targeted strategies to improve outcomes in these patients.

To understand these clinical outcomes in CHD patients, we used the California inpatient database to identify all admissions for HF over a 7‐year period. We compared the outcomes during admissions and the 30‐day readmission rates for adults with and without CHD.

Methods {#jah34352-sec-0009}
=======

The data that support the findings of this study are available from the corresponding author on reasonable request. The data source for this study is the Health Care Utilization Project California State Inpatient Database. This database includes all in‐hospital patients, regardless of payor, from 98.3% of all California hospitals, providing a unique view of statewide inpatient care, and includes over 3.5 million discharges per year.[13](#jah34352-bib-0013){ref-type="ref"}

We retrospectively examined all discharges in the California State Inpatient database between January 1, 2005, and January 1, 2012, with an *International Classification of Diseases, Ninth Revision* (*ICD‐9*‐*CM*) diagnosis code for HF (Table [1](#jah34352-tbl-0001){ref-type="table"}). State Inpatient Database includes a variable listing the Agency for Healthcare Research and Quality\'s single‐level Clinical Classification System (CCS) code for the primary diagnosis.[14](#jah34352-bib-0014){ref-type="ref"} The CCS system provides a way to classify diagnoses and procedures into a limited number of categories by aggregating individual *ICD‐9‐CM* codes into broad diagnosis and procedure groups to facilitate statistical analysis and reporting. If the single‐level CCS code of 108 was present, then it was considered that the primary admitting diagnosis for the patient was HF. Individual patients were the unit of analyses.

###### 

*ICD‐9* Diagnostic Codes

  Diagnosis                 *ICD‐9* Codes
  ------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  HF                        402.01, 402.11, 402.91, 404.91, 404.93, 404.01, 404.03, 428.x
  Anemia                    648.2.x, 280.x--285.x
  Hypertension              437.2, 401.x--405.x
  Hyperlipidemia            272.0, 272.2, 272.4
  Diabetes mellitus         791.5, V458.5, V539.1, V654.6, 249.x, 250.x
  Coronary artery disease   360.1, 360.2, 360.3, 360.4, 360.5, 360.6, 360.7, 360.9, 361.0, 361.1, 361.2, 361.3, 361.4, 361.5, 361.6, 361.7, 361.8, 361.9, 411.0, 411, 411.1, 411.8, 411.89, 412, 412.0, V458.1, V458.2, 429.7, 401.x, 413.x, 414.x
  Atrial arrhythmia         427.31, 427.32, 427.0
  VT/VF or SCA              427.1, 427.4, 427.41, 427.42, 427.5, V125.3
  Lung disease              491.8, 491.9, 492.0, 492.8, 494, 494.0, 494.1, 496, 491.2, 493.x
  Chronic renal failure     V420, V451, V451.1, V451.2, V560, V561, V562, V563.1, V563.2, V568, V56, 585.x
  Cerebrovascular disease   430, 431, 432.x--435.x, 438.x
  Depression                296.2, 296.3, 298.0, 300.4, 309.0, 309.1, 311.0

HF indicates heart failure; VT/VF or SCA, ventricular tachycardia, ventricular fibrillation or sudden cardiac arrest; *ICD‐9*,*International Classification of Diseases, Ninth Revision*.

x designates all diagnosis codes under the listed category, e.g., 280.x includes 280.0, 280.1, 280.8, and 280.9.

Patients were designated as having CHD if their discharge abstract included any of the *ICD‐9* codes for CHD (Table [2](#jah34352-tbl-0002){ref-type="table"}). They were then categorized, on the basis of their anatomic subgroups, as complex and noncomplex CHD using the definitions previously described.[9](#jah34352-bib-0009){ref-type="ref"}, [15](#jah34352-bib-0015){ref-type="ref"}, [16](#jah34352-bib-0016){ref-type="ref"} Complex CHD included "any CHD with pulmonary arterial hypertension," univentricular heart defects (including hypoplastic left heart syndrome), transposition of the great arteries, tetralogy of Fallot, truncus arteriosus, and endocardial cushion defects. All other CHD defects were classified as noncomplex. Patients with both a complex and a noncomplex CHD diagnosis were assigned to the complex CHD group. For patients with codes for more than 1 CHD diagnosis, we used the hierarchical algorithm proposed by Broberg et al[17](#jah34352-bib-0017){ref-type="ref"} to designate 1 condition per patient as their principal CHD diagnosis. As described by Broberg et al[17](#jah34352-bib-0017){ref-type="ref"} and like Burchill et al,[9](#jah34352-bib-0009){ref-type="ref"} we excluded patients with atrial septal defect since their *ICD* codes have lower specificity for CHD and are often used on patients who only have a patent foramen ovale.

###### 

Types of CHD Lesions and Their *ICD‐9* Codes

                                                         *ICD 9* Codes
  ------------------------------------------------------ ------------------------------------------------------------------------
  Complex lesions                                        
  CHD and pulmonary hypertension                         Any code below AND 416.0, 416.8, 416.9
  Univentricular heart/hypoplastic left heart syndrome   745.3, 746.7
  Transposition complex                                  745.10, 745.11, 745.12, 745.19
  Tetralogy of Fallot                                    745.2
  Truncus arteriosus                                     745.0
  Endocardial cushion defect                             745.6
  Noncomplex lesions                                     
  Aortic coarctation                                     747.10
  Ebstein\'s anomaly                                     746.2
  Anomalies of the pulmonary valve                       746.0, 746.02, 746.09
  Anomalies of veins                                     747.4, 747.41, 747.42, 747.49
  Ventricular septal defect                              745.4
  Patent ductus arteriosus                               747.0
  Congenital aortic stenosis/insufficiency               746.3, 746.4
  Congenital mitral stenosis/insufficiency               746.5, 746.6
  Anomalies of the pulmonary artery                      747.3
  Congenital tricuspid valve disease                     746.1
  Unspecified defect of septal closure                   745.9
  Other specified cardiac anomalies                      746.80, 746.81, 746.82, 746.83, 746.84, 746.85, 746.86, 746.87, 746.89

CHD indicates congenital heart disease; HF, heart failure; *ICD‐9*,*International Classification of Diseases, Ninth Revision*.

Clinical characteristics assessed at admission included age, sex, race, and comorbidities. Medical comorbidities were identified from the *ICD‐9* diagnosis codes previously used in the literature (Table [1](#jah34352-tbl-0001){ref-type="table"})[18](#jah34352-bib-0018){ref-type="ref"}, [19](#jah34352-bib-0019){ref-type="ref"} and were considered to be present only if the codes were recorded to be present on admission. A Charlson comorbidity index was calculated for each patient.[20](#jah34352-bib-0020){ref-type="ref"}

Study Outcomes {#jah34352-sec-0010}
--------------

The primary study outcome was any adverse event, and included any in‐hospital adverse event during the index admission or readmission within 30 days. An adverse event was considered in‐hospital if the relevant diagnosis was not present on admission. In‐hospital events evaluated included length of stay (LOS) ≥7 days, incident arrhythmias (atrial arrhythmia or in‐hospital ventricular tachycardia/sudden cardiac arrest), and all‐cause in‐hospital mortality. We used *ICD‐9* diagnosis codes to identify these events (Table [1](#jah34352-tbl-0001){ref-type="table"}). The database included a record linkage number that can be used to identify sequential visits for a patient within California, even if those visits occur at a different facility or setting (inpatient, emergency department, or ambulatory surgery) than the index admission. We used this record linkage number to determine whether a patient had an adverse event of any readmission and if the readmission was for HF or arrhythmia within 30 days after their HF hospitalization. Only the first readmission was considered. We determined the primary reason for readmission (HF versus arrhythmia), and all‐cause mortality during the readmission. We assigned patients with the Agency for Healthcare Research and Quality single‐level CCS codes of 108 as having a primary readmission diagnosis of HF and those with CCS codes of 106 or 107 as having a primary readmission diagnosis of arrhythmia.

Statistical Analysis {#jah34352-sec-0011}
--------------------

Data were analyzed from April 4, 2017 through November 1, 2018. Continuous variables are presented as mean (±SD) or median (interquartile range) as appropriate, while categorical variables are presented as percentages. A Student *t* test or Kruskal--Wallis rank test as appropriate was used for comparisons of continuous variables and Pearson χ^2^ test for categorical variables. We calculated odds ratios for in‐hospital events comparing patients with CHD to the reference group without CHD, adjusting for the following covariates: admission year, age, sex, race, household income, primary payor, and Charlson comorbidity index. A similar analysis was also performed to compare complex and noncomplex CHD subgroups. Because the data use agreement for the database requires it, results for patient groups with fewer than 10 patients are not reported, although the exact number is known to the investigators and used in the analyses. Statistical analyses were performed using STATA/SE software (version 14; StataCorp).

This study used previously collected deidentified data and was, therefore, exempted from institutional review board approval.

Results {#jah34352-sec-0012}
=======

Study Population {#jah34352-sec-0013}
----------------

From a total of 27 907 535 inpatient hospital discharges for adults in California between January 1, 2005 and January 1, 2012, we identified 203 759 patients who were admitted with the primary diagnosis of HF (Figure [1](#jah34352-fig-0001){ref-type="fig"}). After excluding atrial septal defect, 539 of these patients had CHD. The proportion of HF hospitalizations with CHD increased from 0.23% to 0.33% over the study period (*P*=0.01 for trend).

![Study population. ASD indicates atrial septal defect; CA, California; CHD, congenital heart disease; HF, heart failure; SID, state inpatient database.](JAH3-8-e012595-g001){#jah34352-fig-0001}

Baseline Demographics {#jah34352-sec-0014}
---------------------

Patients with CHD had fewer medical comorbidities upon admission than non‐CHD patients, including the comorbidities of anemia, hypertension, hyperlipidemia, diabetes mellitus, coronary artery disease, lung disease, chronic renal failure, and cerebrovascular disease (Table [3](#jah34352-tbl-0003){ref-type="table"}). Charlson Comorbidity Index was thus lower among patients with CHD than non‐CHD patients. Only history of ventricular arrhythmias was more common in CHD patients than non‐CHD patients.

###### 

Baseline Characteristics of Patients Admitted for HF

                                                          CHD (n=539)                                        No CHD (n=202 814)   *P* Value[a](#jah34352-note-0004){ref-type="fn"}
  ------------------------------------------------------- -------------------------------------------------- -------------------- --------------------------------------------------
  Age (y), mean±SD                                        54.9±14.7                                          72.6±14.7            0.0001
  18--39 y, n (%)                                         117 (21.7)                                         5102 (2.5)           \<0.0001
  40--64 y, n (%)                                         252 (46.8)                                         51 369 (25.3)        
  65+ y, n (%)                                            170 (31.5)                                         146 343 (72.2)       
  Males                                                   310 (57.5)                                         101 996 (50.3)       0.001
  Race/ethnicity[b](#jah34352-note-0005){ref-type="fn"}                                                                           
  White                                                   306 (60.1)                                         11 661 (62.4)        0.09
  Black                                                   42 (8.3)                                           20 146 (10.3)        
  Hispanic                                                113 (22.2)                                         34 095 (18.0)        
  Asian or Pacific Islander                               37 (7.3)                                           14 508 (7.4)         
  Other                                                   11 (2.2)                                           3631 (1.9)           
  Comorbidities present on admission                                                                                              
  Anemia                                                  104 (19.3)                                         57 085 (28.2)        \<0.001
  Hypertension                                            232 (43.0)                                         143 832 (70.9)       \<0.001
  Hyperlipidemia                                          126 (23.4)                                         71 162 (35.1)        \<0.001
  Diabetes mellitus                                       95 (17.6)                                          76 814 (37.9)        \<0.001
  CAD                                                     136 (25.2)                                         88 929 (43.9)        \<0.001
  Atrial arrhythmias                                      176 (32.7)                                         65 855 (32.5)        0.9
  Ventricular arrhythmias                                 43 (7.9)                                           7604 (3.8)           \<0.001
  Lung disease                                            96 (17.8)                                          55 454 (27.3)        \<0.001
  Chronic renal failure                                   59 (10.9)                                          44 079 (21.7)        \<0.001
  Cerebrovascular disease                                 ≤10 (1.3)[c](#jah34352-note-0006){ref-type="fn"}   6879 (3.4)           0.007
  Depression                                              34 (6.3)                                           13 750 (6.8)         0.62
  Charlson comorbidity index                              2.1±0.9                                            2.5±1.2              0.0001

Values are mean±SD or number (percent of total). CAD indicates coronary artery disease; CHD, congenital heart disease; HF, heart failure.

Calculated using Pearson χ^2^ test.

Because of missing data, totals may not equal column heads.

Health Care Cost and Utilization Project policy prohibits reporting cell frequencies of \<10.

Clinical Events {#jah34352-sec-0015}
---------------

Patients with CHD had higher incidence of any adverse event than non‐CHD patients (40.5% versus 29.0%, *P*\<0.001). The rates of any in‐hospital event, LOS ≥7 days, and incident arrhythmia were higher in CHD patients than non‐CHD patients (Figure [2](#jah34352-fig-0002){ref-type="fig"}A). Median LOS was longer for CHD patients than non‐CHD patients (4 \[interquartile range: 2.7\] versus 3 \[interquartile range: 2.6\] days, *P*=0.0001). Fifteen percent of patients with HF hospitalizations (30 317 of 203 353) had any 30‐day readmission; 88 (16.3%) had CHD, and 30 229 (14.9%) did not. We found no significant difference in the rates of readmission events between CHD patients and non‐CHD patients (Figure [2](#jah34352-fig-0002){ref-type="fig"}B).

![Rates of in‐hospital and 30‐day readmission events in CHD and non‐CHD patients admitted for HF. **A**, In‐hospital events (\**P*\<0.01). **B**, 30‐day readmission events. CHD indicates congenital heart disease; HF, heart failure; LOS, length of stay.](JAH3-8-e012595-g002){#jah34352-fig-0002}

After adjusting for covariates, CHD patients had higher odds of an adverse event than non‐CHD patients (adjusted odds ratio 2.1 (95% CI: 1.7--2.5), *P*\<0.001). Of the individual adverse events, CHD patients had higher adjusted odds of any in‐hospital event, LOS ≥7 days, incident arrhythmias, in‐hospital mortality, and a lower adjusted odds of 30‐day readmission for HF (Figure [3](#jah34352-fig-0003){ref-type="fig"}A). Among patients admitted for HF with CHD, those with complex lesions had significantly higher odds of LOS ≥7 days than patients with noncomplex lesions but no difference in the odds of other outcomes (Figure [3](#jah34352-fig-0003){ref-type="fig"}B).

![Multivariate analysis for adverse clinical outcomes in patients admitted for HF, comparing (**A**) CHD and non‐CHD patients; and (**B**) complex and noncomplex CHD patients. \*Adjusted for admission year, age, sex, race, household income, primary payor, and Charlson comorbidity index. AOR indicates adjusted odds ratio; CHD, congenital heart disease; HF, heart failure.](JAH3-8-e012595-g003){#jah34352-fig-0003}

Discussion {#jah34352-sec-0016}
==========

It has been reported that adults with CHD have higher resource use during their HF hospitalizations than HF patients who do not have CHD.[9](#jah34352-bib-0009){ref-type="ref"} Yet it has not been known whether the clinical outcomes for CHD patients with HF differ from the outcomes for non‐CHD patients with HF. In this study of ≈200 000 patients admitted for HF in California during a 7‐year period, we found that adults with CHD had significantly more adverse in‐hospital clinical events than those without CHD, including 2.5‐, 2.8‐, and 1.9‐fold higher adjusted odds of longer LOS, incident arrhythmias, and in‐hospital mortality, respectively. On the other hand, CHD patients had 40% lower adjusted odds of 30‐day readmission for HF after their HF admission.

We found CHD patients to be younger than non‐CHD patients during their HF admission, similar to the prior study by Burchill et al.[9](#jah34352-bib-0009){ref-type="ref"} This may be because of the direct time‐dependent impact of the underlying structural and functional abnormalities on cardiac function, resulting in HF at a younger age. The rates of some comorbidities (ie, diabetes mellitus, coronary artery disease, lung, and renal disease) in our adult CHD HF patients was similar to what was previously reported by Burchill et al,[9](#jah34352-bib-0009){ref-type="ref"} but our CHD HF patients had higher rates of hypertension (43% versus 28%). This is likely because of the differences in the *ICD‐9* codes used to define hypertension. Overall, in both our study and the Burchill et al study, CHD patients admitted for HF had lower comorbidity indices than non‐CHD patients.[9](#jah34352-bib-0009){ref-type="ref"}

While the median LOS for CHD adults in our study was 4 days, it was much higher (7 and 7.2 days) in the 2 prior studies (Burchill et al and Chan et al, respectively)[9](#jah34352-bib-0009){ref-type="ref"}, [21](#jah34352-bib-0021){ref-type="ref"} that reported LOS during a HF hospitalization among CHD patients. This could be related to differences in the study population. Burchill et al included in their study any patient with a HF diagnosis, not just those for whom HF was the primary diagnosis. As a result, their study population included many patients admitted for procedures, and those patients have longer average LOS. Chan et al obtained data for adult CHD patients from pediatric hospitals. While these patients had longer median LOS among high resource use pediatric centers, the median LOS for lower resource use centers was similar to our study of nearly all hospitals statewide. Additionally, similar to Burchill et al, we also found that CHD patients had a longer LOS than non‐CHD patients during their HF hospitalization.[9](#jah34352-bib-0009){ref-type="ref"} This might be because of the differences in HF management between the 2 study groups. The management of HF in CHD patients is usually directed towards identifying and correcting any underlying mechanical or hemodynamic abnormalities.[22](#jah34352-bib-0022){ref-type="ref"}, [23](#jah34352-bib-0023){ref-type="ref"} However, conventional HF medications have been less effective and may even be harmful, such as the use of beta blockers in CHD patients with prevalent pre‐existing sinus node dysfunction, heart block, baffle stenosis, nondistensible atria, or restrictive ventricular physiology.[6](#jah34352-bib-0006){ref-type="ref"}

For some CHD patients, arrhythmias are intrinsic to the structural malformation itself, while for most others, arrhythmias represent an acquired condition related to the unique myocardial substrate created by surgical scars in conjunction with cyanosis and abnormal pressure/volume loads of long duration.[24](#jah34352-bib-0024){ref-type="ref"} We observed ≈33% and 8% prevalence of atrial and ventricular arrhythmia, respectively, at the time of admission for HF in adults with CHD. This estimate was higher than the 25% to 32% prevalence of all arrhythmia noted in a national sample of adult CHD admissions for any cause.[25](#jah34352-bib-0025){ref-type="ref"}, [26](#jah34352-bib-0026){ref-type="ref"} Our finding also supports the notion that arrhythmias have serious implications in CHD patients, whether it is a cause of or result from HF.[6](#jah34352-bib-0006){ref-type="ref"}, [27](#jah34352-bib-0027){ref-type="ref"} There are little data on the incidence of new arrhythmias during admissions for HF among CHD patients. In our study, 3.5% of adult CHD patients had incident arrhythmias during their HF hospitalization, representing a 2.8‐fold higher adjusted odds for this adverse outcome than for non‐CHD patients.

The overall in‐hospital mortality rate of 3% in our study is lower than the 6.5% noted by Burchill et al and 7.3% noted by Chan et al.[9](#jah34352-bib-0009){ref-type="ref"}, [21](#jah34352-bib-0021){ref-type="ref"} The increased mortality noted in those studies may be related to more complicated admissions, as suggested by their longer LOS. Similar to Burchill et al, we found the in‐hospital mortality rates to be similar for CHD and non‐CHD HF patients, but we found that the adjusted odds of inpatient mortality was nearly 2‐fold higher in CHD patients. Given the limited sample size of the CHD patients in our data set and the absence of clinical details, we were not able to explore the predictors of high mortality among them. However, future studies could address the hypotheses that heterogeneity of the underlying anatomy, surgical repairs, and the physiologic severity of the CHD lesions as well as the chronic nature of cardiac remodeling may cause progressive modulation of the arrhythmia and hemodynamic substrate, leading to higher inpatient mortality.

We found that only 15% of all patients with a HF admission had a 30‐day readmission. This is lower than the 25% rate of 30‐day readmission noted in a prior study of Medicare beneficiaries.[12](#jah34352-bib-0012){ref-type="ref"} In that study, 35% of patients who were readmitted were rehospitalized with a primary diagnosis of HF, while we found these readmission rates to be 23% and 29% in our CHD and non‐CHD patients, respectively. CHD patients in our study also had 40% lower adjusted odds of 30‐day readmission for HF after their HF admission than non‐CHD patients. As mentioned earlier, the management of HF during admission is usually targeted toward correcting the underlying structural or hemodynamic abnormalities. This might reduce the risk for recurrent HF hospitalization, at least in the short term. This could explain why we observed significantly lower 30‐day readmission for HF in CHD patients despite no difference in the odds of 30‐day readmission between the CHD and non‐CHD groups. In general, readmission is known to be a major healthcare burden for CHD patients after a hospitalization, and the type of CHD lesion is shown to be the primary risk factor for the readmission.[28](#jah34352-bib-0028){ref-type="ref"}, [29](#jah34352-bib-0029){ref-type="ref"} Because of the small sample size of CHD patients who had a readmission after their HF admission, we were unable to explore potential differences in readmission events specific to each lesion.

Our findings highlight that during admission for HF, CHD patients---who are younger with fewer comorbidities than non‐CHD patients admitted with HF---nonetheless had significantly higher adjusted risks of adverse clinical outcomes than non‐CHD patients. Further studies to identify predictors of incident arrhythmias and in‐hospital mortality during HF admission in CHD patients, such as those specific to CHD lesions, may assist in the development of lesion‐specific risk prediction models and targeted prevention and treatment protocols.

Limitations {#jah34352-sec-0017}
-----------

This study has several limitations, primarily intrinsic to the use of the hospital discharge abstract database.[30](#jah34352-bib-0030){ref-type="ref"} First, *ICD‐9* codes have imperfect sensitivity and specificity, and CHD may have been incorrectly coded. Because of this, we excluded patients with atrial septal defect, since it is known that coding for atrial septal defect versus patent foramen ovale is frequently incorrect.[17](#jah34352-bib-0017){ref-type="ref"} Second, clinical detail is often missing from discharge abstracts; thus inherent patient differences, variations in clinical presentation, information regarding medication use, and similar characteristics during the hospitalization could not be studied. Finally, the inpatient nature of this database did not allow us to capture out‐of‐hospital events or mortality, or intensity and quality of care before and after hospitalization with HF. Similarly, only patients who were readmitted to a California hospital were captured; therefore, we had no information about deaths among patients who were admitted or died out of state.

Conclusions {#jah34352-sec-0018}
===========

In this study of nearly all patients with HF hospitalizations in California hospitals during a 7‐year period, CHD patients admitted for HF are younger and have fewer comorbidities than patients without CHD. Despite this, patients with CHD have higher adjusted odds of longer LOS, incident arrhythmias, and in‐hospital mortality than non‐CHD patients. The higher risks for adverse clinical outcomes during their admissions for HF among CHD patients suggest a need for CHD‐specific risk prediction tools and HF treatment recommendations to improve outcomes in these patients.
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